乳腺がん治療の市場規模、シェア、動向分析レポート：治療別、最終用途別、地域別、セグメント別予測、2024年～2030年

乳腺がん治療市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、世界の乳腺がん治療市場規模は2030年までに428億7,000万米ドルに達すると予測され、2024年から2030年までのCAGRは9.1％で成長すると予測されています。

この成長は、治療技術の進歩、乳房腺がんの有病率の増加、個別化医療への注目の高まりが大きな原動力となっています。全米乳がん財団によると、米国では女性の8人に1人が一生の間に乳がんと診断されます。2024年には、推定310,720人の女性と2,800人の男性が浸潤性乳がんと診断されると予想されています。最も早期の限局期で診断された乳がんの5年相対生存率は99％です。早期発見と治療の進歩により、近年の生存率は著しく改善し、現在米国では400万人以上の乳がん生存者がいます。

乳がんの一般的な形態である乳腺がんは、標的療法、免疫療法、ホルモン療法を含むさまざまな革新的治療によって対処されています。市場規模の拡大は、治療効果を高め、患者の予後を改善する新薬や治療法の継続的な開拓に起因しています。さらに、乳がんに対する意識の高まりと早期発見の重要性が、先進的な治療オプションに対する需要の高まりに寄与しています。

高齢化や罹患率の上昇と相まって、乳がんの世界の負担が増加していることも市場拡大に拍車をかけています。先進的な治療法を求める患者が増え、ヘルスケア・システムが最先端技術に投資するにつれて、乳腺がん治療市場は大きく成長するとみられます。ゲノム・プロファイリングやバイオマーカー同定などの精密医療における技術の進歩は、より個別化された治療アプローチを可能にしています。これらの技術革新は、副作用を最小限に抑えながら、がん細胞をより効果的に標的とすることを可能にし、患者の全体的な体験を向上させる。さらに、現在進行中の調査や臨床試験により、新規治療や併用療法が導入される可能性が高く、市場の成長をさらに促進する可能性があります。

乳腺がん治療市場レポート・ハイライト

• 標的治療セグメントは2023年に27.6%の最大シェアを占めました。この優位性は、より精密で効果的な治療法へのシフトを反映し、乳がん治療における標的治療の変革的なインパクトを強調するものです。
• 病院セグメントは2023年に60.0％以上の最大シェアを占めました。この成長は、乳がんの有病率の高さによるところが大きく、病院ベースの治療に対する大きな需要を牽引しています。
• 市場の著名なプレーヤーとしては、Merck &Co;Bristol Myers Squibb;協和キリン;Eisai Co.サノフィ、ファイザー、アストラゼネカ、ノバルティス、イーライリリー・アンド・カンパニー、F.ホフマン・ラ・ロシュなどです。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 乳腺がん治療市場の変数、動向、範囲

• 市場系統の見通し
  • 親市場の見通し
  • 関連/付随市場見通し
• 市場力学
  • 市場促進要因分析
  • 市場抑制要因分析
• 乳腺がん治療市場分析ツール
  • 業界分析- ポーターのファイブフォース分析
  • PESTEL分析
  • COVID-19の影響

第4章 世界の乳腺がん治療市場：治療別推定・動向分析

• 世界の乳腺がん治療市場：治療ダッシュボード
• 世界の乳腺がん治療市場：治療変動分析
• 世界の乳腺がん治療市場、治療別
• 化学療法
• 標的療法
• ホルモン療法
• 免疫療法
• 放射線治療
• その他

第5章 乳腺がん治療市場：最終用途別推定・動向分析

• 世界の乳腺がん治療市場：最終用途ダッシュボード
• 世界の乳腺がん治療市場：最終用途変動分析
• 世界の乳腺がん治療市場、最終用途別
• 病院
• 専門クリニック
• その他

第6章 乳腺がん治療市場： 地域別推定・動向分析、治療別、最終用途別。

• 地域市場ダッシュボード
• 市場規模、予測動向分析、2018年から2030年：
• 北米
• 欧州
• アジア太平洋
• ラテンアメリカ
• 中東・アフリカ

第7章 競合情勢

• 主要市場参入企業による最近の動向と影響分析
• 企業/競合の分類
• ベンダー情勢
  • 主要販売代理店およびチャネルパートナーのリスト
  • 主要顧客
  • 主要企業のヒートマップ分析、2023 年
• 企業プロファイル
  • Merck &Co
  • Bristol Myers Squiib
  • Kyowa Kirin
  • Eisai Co.Ltd
  • Sanofi
  • Pfizer Inc
  • AstraZeneca
  • Novartis AG
  • Eli Lilly and Company
  • F. Hoffmann La Roche AG

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
• Table 3 North America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 4 North America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 5 U.S. Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 6 U.S. Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 7 Canada Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 8 Canada Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 9 Europe Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
• Table 10 Europe Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 11 Europe Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 12 Germany Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 13 Germany Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 14 UK Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 15 UK Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 16 France Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 17 France Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 18 Italy Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 19 Italy Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 20 Spain Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 21 Spain Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 22 Denmark Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 23 Denmark Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 24 Sweden Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 25 Sweden Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 26 Norway Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 27 Norway Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 28 Asia Pacific Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
• Table 29 Asia Pacific Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 30 Asia Pacific Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 31 China Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 32 China Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 33 Japan Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 34 Japan Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 35 India Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 36 India Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 37 South Korea Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 38 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 39 South Korea Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 40 Australia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 41 Australia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 42 Thailand Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 43 Thailand Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 44 Latin America Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
• Table 45 Latin America Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 46 Latin America Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 47 Brazil Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 48 Brazil Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 49 Mexico Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 50 Mexico Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 51 Argentina Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 52 Argentina Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 53 MEA Breast Adenocarcinoma Treatment market, by country, 2018 - 2030 (USD Billion)
• Table 54 MEA Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 55 MEA Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 56 South Africa Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 57 South Africa Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 58 Saudi Arabia Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 59 Saudi Arabia Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 60 UAE Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 61 UAE Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)
• Table 62 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 63 Kuwait Breast Adenocarcinoma Treatment market, by treatment, 2018 - 2030 (USD Billion)
• Table 64 Kuwait Breast Adenocarcinoma Treatment market, by end use, 2018 - 2030 (USD Billion)

List of Figures

• Fig. 1 Market research process
• Fig. 2 Data triangulation techniques
• Fig. 3 Primary research pattern
• Fig. 4 Market research approaches
• Fig. 5 Value-chain-based sizing & forecasting
• Fig. 6 QFD modeling for market share assessment
• Fig. 7 Market formulation & validation
• Fig. 8 Breast Adenocarcinoma Treatment Market: Market Outlook
• Fig. 9 Breast Adenocarcinoma Treatment Competitive Insights
• Fig. 10 Parent market outlook
• Fig. 11 Related/ancillary market outlook
• Fig. 12 Penetration and growth prospect mapping
• Fig. 13 Industry value chain analysis
• Fig. 14 Breast Adenocarcinoma Treatment Market Driver Impact
• Fig. 15 Breast Adenocarcinoma Treatment Market Restraint Impact
• Fig. 16 Breast Adenocarcinoma Treatment Market Strategic Initiatives Analysis
• Fig. 17 Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
• Fig. 18 Breast Adenocarcinoma Treatment Market: Treatment Outlook And Key Takeaways
• Fig. 19 Chemotherapy market estimates and forecast, 2018 - 2030
• Fig. 20 Targeted therapy market estimates and forecast, 2018 - 2030
• Fig. 21 Hormonal therapy market estimates and forecast, 2018 - 2030
• Fig. 22 Immunotherapy market estimates and forecast, 2018 - 2030
• Fig. 23 Radiation therapy market estimates and forecast, 2018 - 2030
• Fig. 24 Other market estimates and forecast, 2018 - 2030
• Fig. 25 Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
• Fig. 26 Breast Adenocarcinoma Treatment Market: End Use Outlook And Key Takeaways
• Fig. 27 Hospitals market estimates and forecast, 2018 - 2030
• Fig. 28 Specialty clinics market estimates and forecast, 2018 - 2030
• Fig. 29 Global Breast Adenocarcinoma Treatment Market: Regional Movement Analysis
• Fig. 30 Global Breast Adenocarcinoma Treatment Market: Regional Outlook And Key Takeaways
• Fig. 31 Global Breast Adenocarcinoma Treatment market share and leading companies
• Fig. 32 North America: SWOT
• Fig. 33 Europe SWOT
• Fig. 34 Asia Pacific SWOT
• Fig. 35 Latin America SWOT
• Fig. 36 MEA SWOT
• Fig. 37 North America, by country
• Fig. 38 North America
• Fig. 39 North America market estimates and forecasts, 2018 - 2030
• Fig. 40 U.S.
• Fig. 41 U.S. market estimates and forecasts, 2018 - 2030
• Fig. 42 Canada
• Fig. 43 Canada market estimates and forecasts, 2018 - 2030
• Fig. 44 Mexico
• Fig. 45 Mexico market estimates and forecasts, 2018 - 2030
• Fig. 46 Europe
• Fig. 47 Europe market estimates and forecasts, 2018 - 2030
• Fig. 48 UK
• Fig. 49 UK market estimates and forecasts, 2018 - 2030
• Fig. 50 Germany
• Fig. 51 Germany market estimates and forecasts, 2018 - 2030
• Fig. 52 France
• Fig. 53 France market estimates and forecasts, 2018 - 2030
• Fig. 54 Italy
• Fig. 55 Italy market estimates and forecasts, 2018 - 2030
• Fig. 56 Spain
• Fig. 57 Spain market estimates and forecasts, 2018 - 2030
• Fig. 58 Denmark
• Fig. 59 Denmark market estimates and forecasts, 2018 - 2030
• Fig. 60 Sweden
• Fig. 61 Sweden market estimates and forecasts, 2018 - 2030
• Fig. 62 Norway
• Fig. 63 Norway market estimates and forecasts, 2018 - 2030
• Fig. 64 Asia Pacific
• Fig. 65 Asia Pacific market estimates and forecasts, 2018 - 2030
• Fig. 66 China
• Fig. 67 China market estimates and forecasts, 2018 - 2030
• Fig. 68 Japan
• Fig. 69 Japan market estimates and forecasts, 2018 - 2030
• Fig. 70 India
• Fig. 71 India market estimates and forecasts, 2018 - 2030
• Fig. 72 Singapore
• Fig. 73 Singapore market estimates and forecasts, 2018 - 2030
• Fig. 74 South Korea
• Fig. 75 South Korea market estimates and forecasts, 2018 - 2030
• Fig. 76 Australia
• Fig. 77 Australia market estimates and forecasts, 2018 - 2030
• Fig. 78 Latin America
• Fig. 79 Latin America market estimates and forecasts, 2018 - 2030
• Fig. 80 Brazil
• Fig. 81 Brazil market estimates and forecasts, 2018 - 2030
• Fig. 82 Argentina
• Fig. 83 Argentina market estimates and forecasts, 2018 - 2030
• Fig. 84 Middle East and Africa
• Fig. 85 Middle East and Africa market estimates and forecasts, 2018 - 2030
• Fig. 86 South Africa
• Fig. 87 South Africa market estimates and forecasts, 2018 - 2030
• Fig. 88 Saudi Arabia
• Fig. 89 Saudi Arabia market estimates and forecasts, 2018 - 2030
• Fig. 90 UAE
• Fig. 91 UAE market estimates and forecasts, 2018 - 2030
• Fig. 92 Kuwait
• Fig. 93 Kuwait market estimates and forecasts, 2018 - 2030
• Fig. 94 Market share of key market companies - Breast Adenocarcinoma Treatment market

Breast Adenocarcinoma Treatment Market Growth & Trends:

The global breast adenocarcinoma treatment market size is expected to reach USD 42.87 billion by 2030 and is projected to grow at a CAGR of 9.1% from 2024 to 2030, according to a new report by Grand View Research, Inc. This growth is significantly driven by the advancements in treatment technologies, the increasing prevalence of breast adenocarcinoma, and a growing focus on personalized medicine. According to the National Breast Cancer Foundation, in the U.S., 1 in 8 women will be diagnosed with breast cancer during their lifetime. For 2024, an estimated 310,720 women and 2,800 men are expected to be diagnosed with invasive breast cancer. The 5-year relative survival rate for breast cancer diagnosed at its earliest, localized stage is 99%. Advances in early detection and treatment have markedly improved survival rates in recent years, resulting in over 4 million breast cancer survivors currently living in the U.S.

Breast adenocarcinoma, a common form of breast cancer, is being addressed through a range of innovative treatments that include targeted therapies, immunotherapies, and hormonal therapies. The rise in market size can be attributed to the continual development of new drugs and therapies that enhance treatment efficacy and improve patient outcomes. In addition, the increasing awareness of breast cancer and the importance of early detection are contributing to a higher demand for advanced treatment options.

The increasing global burden of breast cancer, coupled with an aging population and rising incidence rates, is also fueling market expansion. As more patients seek advanced treatment options and healthcare systems invest in cutting-edge technologies, the market for breast adenocarcinoma treatments is set to grow significantly. Technological advancements in precision medicine, such as genomic profiling and biomarker identification, are enabling more personalized treatment approaches. These innovations allow for more effective targeting of cancer cells while minimizing side effects, thus enhancing the overall patient experience. Furthermore, ongoing research and clinical trials are likely to introduce novel therapies and combination treatments that could further drive market growth.

Breast Adenocarcinoma Treatment Market Report Highlights:

• The targeted therapy segment held the largest share of 27.6 % in 2023. This prominence underscores the transformative impact of targeted therapies on breast cancer treatment, reflecting a shift towards more precise and effective treatment modalities.
• The hospitals segment held the largest share of more than 60.0% in 2023. This growth is largely due to the high prevalence of breast cancer, which drives significant demand for hospital-based treatments.
• Some of the prominent players in market are Merck & Co; Bristol Myers Squibb; Kyowa Kirin; Eisai Co. Ltd; Sanofi; Pfizer Inc; AstraZeneca; Novartis AG; Eli Lilly and Company; F. Hoffmann La Roche AG

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Treatment
  • 1.1.2. End Use
  • 1.1.3. Regional scope
  • 1.1.4. Estimates and forecast timeline.
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased database.
  • 1.3.2. GVR's internal database
  • 1.3.3. Secondary sources
  • 1.3.4. Primary research
  • 1.3.5. Details of primary research
• 1.4. Information or Data Analysis
  • 1.4.1. Data analysis models
• 1.5. Market Formulation & Validation
• 1.6. Model Details
  • 1.6.1. Commodity flow analysis (Model 1)
  • 1.6.2. Approach 1: Commodity flow approach
  • 1.6.3. Volume price analysis (Model 2)
  • 1.6.4. Approach 2: Volume price analysis
• 1.7. List of Secondary Sources
• 1.8. List of Primary Sources
• 1.9. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Treatment Outlook
  • 2.2.2. End Use Outlook
  • 2.2.3. Regional Outlook
• 2.3. Competitive Insights

Chapter 3. Breast Adenocarcinoma Treatment Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
    • 3.2.1.1. Rising Prevalence of Breast Cancer
    • 3.2.1.2. Advancements In Treatment Modalities
  • 3.2.2. Market Restraint Analysis
    • 3.2.2.1. Stringent Regulation And Approvals
    • 3.2.2.2. High Cost of Treatments
• 3.3. Breast Adenocarcinoma Treatment Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. COVID-19 Impact

Chapter 4. Global Breast Adenocarcinoma Treatment Market: Treatment Estimates & Trend Analysis

• 4.1. Global Breast Adenocarcinoma Treatment Market: Treatment Dashboard
• 4.2. Global Breast Adenocarcinoma Treatment Market: Treatment Movement Analysis
• 4.3. Global Breast Adenocarcinoma Treatment Market, Treatment
• 4.4. Chemotherapy
  • 4.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.5. Targeted Therapy
  • 4.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.6. Hormonal Therapy
  • 4.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.7. Immunotherapy
  • 4.7.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.8. Radiation Therapy
  • 4.8.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 4.9. Other
  • 4.9.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 5. Breast Adenocarcinoma Treatment Market: End Use Estimates & Trend Analysis

• 5.1. Global Breast Adenocarcinoma Treatment Market: End Use Dashboard
• 5.2. Global Breast Adenocarcinoma Treatment Market: End Use Movement Analysis
• 5.3. Global Breast Adenocarcinoma Treatment Market, End Use
• 5.4. Hospitals
  • 5.4.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.5. Specialty Clinics
  • 5.5.1. Market estimates and forecast 2018 to 2030 (USD Billion)
• 5.6. Others
  • 5.6.1. Market estimates and forecast 2018 to 2030 (USD Billion)

Chapter 6. Breast Adenocarcinoma Treatment Market: Regional Estimates & Trend Analysis, By Treatment, and By End Use.

• 6.1. Regional Market Dashboard
• 6.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 6.3. North America
  • 6.3.1. U.S.
    • 6.3.1.1. Key country dynamics
    • 6.3.1.2. Regulatory framework/ reimbursement structure
    • 6.3.1.3. Competitive scenario
    • 6.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.2. Canada
    • 6.3.2.1. Key country dynamics
    • 6.3.2.2. Regulatory framework/ reimbursement structure
    • 6.3.2.3. Competitive scenario
    • 6.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.3.3. Mexico
    • 6.3.3.1. Key country dynamics
    • 6.3.3.2. Regulatory framework/ reimbursement structure
    • 6.3.3.3. Competitive scenario
    • 6.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.4. Europe
  • 6.4.1. UK
    • 6.4.1.1. Key country dynamics
    • 6.4.1.2. Regulatory framework/ reimbursement structure
    • 6.4.1.3. Competitive scenario
    • 6.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.2. Germany
    • 6.4.2.1. Key country dynamics
    • 6.4.2.2. Regulatory framework/ reimbursement structure
    • 6.4.2.3. Competitive scenario
    • 6.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.3. France
    • 6.4.3.1. Key country dynamics
    • 6.4.3.2. Regulatory framework/ reimbursement structure
    • 6.4.3.3. Competitive scenario
    • 6.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.4. Italy
    • 6.4.4.1. Key country dynamics
    • 6.4.4.2. Regulatory framework/ reimbursement structure
    • 6.4.4.3. Competitive scenario
    • 6.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.5. Spain
    • 6.4.5.1. Key country dynamics
    • 6.4.5.2. Regulatory framework/ reimbursement structure
    • 6.4.5.3. Competitive scenario
    • 6.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.6. Norway
    • 6.4.6.1. Key country dynamics
    • 6.4.6.2. Regulatory framework/ reimbursement structure
    • 6.4.6.3. Competitive scenario
    • 6.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.7. Sweden
    • 6.4.7.1. Key country dynamics
    • 6.4.7.2. Regulatory framework/ reimbursement structure
    • 6.4.7.3. Competitive scenario
    • 6.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.4.8. Denmark
    • 6.4.8.1. Key country dynamics
    • 6.4.8.2. Regulatory framework/ reimbursement structure
    • 6.4.8.3. Competitive scenario
    • 6.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.5. Asia Pacific
  • 6.5.1. Japan
    • 6.5.1.1. Key country dynamics
    • 6.5.1.2. Regulatory framework/ reimbursement structure
    • 6.5.1.3. Competitive scenario
    • 6.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.2. China
    • 6.5.2.1. Key country dynamics
    • 6.5.2.2. Regulatory framework/ reimbursement structure
    • 6.5.2.3. Competitive scenario
    • 6.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.3. India
    • 6.5.3.1. Key country dynamics
    • 6.5.3.2. Regulatory framework/ reimbursement structure
    • 6.5.3.3. Competitive scenario
    • 6.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.4. Australia
    • 6.5.4.1. Key country dynamics
    • 6.5.4.2. Regulatory framework/ reimbursement structure
    • 6.5.4.3. Competitive scenario
    • 6.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.5. South Korea
    • 6.5.5.1. Key country dynamics
    • 6.5.5.2. Regulatory framework/ reimbursement structure
    • 6.5.5.3. Competitive scenario
    • 6.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.5.6. Singapore
    • 6.5.6.1. Key country dynamics
    • 6.5.6.2. Regulatory framework/ reimbursement structure
    • 6.5.6.3. Competitive scenario
    • 6.5.6.4. Singapore market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.6. Latin America
  • 6.6.1. Brazil
    • 6.6.1.1. Key country dynamics
    • 6.6.1.2. Regulatory framework/ reimbursement structure
    • 6.6.1.3. Competitive scenario
    • 6.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.6.2. Argentina
    • 6.6.2.1. Key country dynamics
    • 6.6.2.2. Regulatory framework/ reimbursement structure
    • 6.6.2.3. Competitive scenario
    • 6.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Billion)
• 6.7. MEA
  • 6.7.1. South Africa
    • 6.7.1.1. Key country dynamics
    • 6.7.1.2. Regulatory framework/ reimbursement structure
    • 6.7.1.3. Competitive scenario
    • 6.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.2. Saudi Arabia
    • 6.7.2.1. Key country dynamics
    • 6.7.2.2. Regulatory framework/ reimbursement structure
    • 6.7.2.3. Competitive scenario
    • 6.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.3. UAE
    • 6.7.3.1. Key country dynamics
    • 6.7.3.2. Regulatory framework/ reimbursement structure
    • 6.7.3.3. Competitive scenario
    • 6.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Billion)
  • 6.7.4. Kuwait
    • 6.7.4.1. Key country dynamics
    • 6.7.4.2. Regulatory framework/ reimbursement structure
    • 6.7.4.3. Competitive scenario
    • 6.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Billion)

Chapter 7. Competitive Landscape

• 7.1. Recent Developments and Impact Analysis, By Key Market Participants
• 7.2. Company/Competition Categorization
• 7.3. Vendor Landscape
  • 7.3.1. List of key distributors and channel partners
  • 7.3.2. Key customers
  • 7.3.3. Key company heat map analysis, 2023
• 7.4. Company Profiles
  • 7.4.1. Merck & Co
    • 7.4.1.1. Company overview
    • 7.4.1.2. Financial performance
    • 7.4.1.3. Product benchmarking
    • 7.4.1.4. Strategic initiatives
  • 7.4.2. Bristol Myers Squiib
    • 7.4.2.1. Company overview
    • 7.4.2.2. Financial performance
    • 7.4.2.3. Product benchmarking
    • 7.4.2.4. Strategic initiatives
  • 7.4.3. Kyowa Kirin
    • 7.4.3.1. Company overview
    • 7.4.3.2. Financial performance
    • 7.4.3.3. Product benchmarking
    • 7.4.3.4. Strategic initiatives
  • 7.4.4. Eisai Co.Ltd
    • 7.4.4.1. Company overview
    • 7.4.4.2. Financial performance
    • 7.4.4.3. Product benchmarking
    • 7.4.4.4. Strategic initiatives
  • 7.4.5. Sanofi
    • 7.4.5.1. Company overview
    • 7.4.5.2. Financial performance
    • 7.4.5.3. Product benchmarking
    • 7.4.5.4. Strategic initiatives
  • 7.4.6. Pfizer Inc
    • 7.4.6.1. Company overview
    • 7.4.6.2. Financial performance
    • 7.4.6.3. Product benchmarking
    • 7.4.6.4. Strategic initiatives
  • 7.4.7. AstraZeneca
    • 7.4.7.1. Company overview
    • 7.4.7.2. Financial performance
    • 7.4.7.3. Product benchmarking
    • 7.4.7.4. Strategic initiatives
  • 7.4.8. Novartis AG
    • 7.4.8.1. Company overview
    • 7.4.8.2. Financial performance
    • 7.4.8.3. Product benchmarking
    • 7.4.8.4. Strategic initiatives
  • 7.4.9. Eli Lilly and Company
    • 7.4.9.1. Company overview
    • 7.4.9.2. Financial performance
    • 7.4.9.3. Product benchmarking
    • 7.4.9.4. Strategic initiatives
  • 7.4.10. F. Hoffmann La Roche AG
    • 7.4.10.1. Company overview
    • 7.4.10.2. Financial performance
    • 7.4.10.3. Product benchmarking
    • 7.4.10.4. Strategic initiatives